The U.S. Food and Drug Administration (FDA) flags data integrity and maintenance problems at a Dabur India manufacturing site, according to reporting from multiple outlets. The issues are linked to an FDA inspection of Dabur’s factory in Dadra and Nagar Haveli conducted in January. The FDA’s findings describe lapses related to how data is maintained and to upkeep practices at the plant. The reports also state that the inspection identifies certain units within the facility that pose risks of microbiological contamination. Dabur, which describes itself as one of the world’s largest suppliers of Ayurvedic products, operates the plant involved in the regulator’s review. The outlets attribute the concerns to the FDA’s observations during the January inspection and note that the findings are issued after the inspection process. The reports do not indicate that the FDA has announced a final enforcement action in the excerpts provided, focusing instead on the regulator’s documented concerns about data handling and facility maintenance, including contamination risk factors.